Company research
Kailera Therapeutics, Inc.
CIK 2096997Updated Sep 26, 2026
SecurityKLRA · NASDAQ · equity
KLRA price & chart
Loading TradingView…
NASDAQ:KLRA on TradingView ↗About the company
We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate that we believe offers the potential for the greatest weight loss.
In the news
Recent filings
4 filing
3 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G filing
Show 5 more recent filings
Offerings
Registration 333-294690
- Gross proceeds
- 625000000.0
- Net proceeds
- 581250000.0
- Deal price
- 16.0
- Shares
- 39062500
- Offering price
- $16.00
- Ticker
- KLRA
Filing attachments
ck0002096997-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 ck0002096997-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates • IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 • Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027 • Expanded executive team to strengthen technical operations capabilities and corporate affairs leadership • Cas…
Read attachment ↗ck0002096997-ex99_1.htm · 8-K · 2026-05-26
EX-99.1 2 ck0002096997-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates • Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline • Initiated five late-stage global clinical trials in obesity, including the ribupatide injection KaiNETIC Phase 3 program • Reported positive topline clinical data from three trials conducted by our partner Hengrui in China, inclu…
Read attachment ↗d113532dex107.htm · S-1 · 2026-03-27
EX-10.7 8 d113532dex107.htm EX-10.7 EX-10.7 Exhibit 10.7 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into on or about January 3, 2025, by and between Kailera Therapeutics, Inc., a Delaware corporation (the “Company”), and Jamie Coleman (the “Executive”), and will be effective as of the Effective Date (as defined below). Certain capitalized terms used, but not otherwise defined, in this Agreement are defined in Section 6 hereof. WHEREAS, the Execu…
Read attachment ↗